Guardant360® is the first clinically available, validated, comprehensive liquid biopsy
Guardant360® is the first clinically validated comprehensive liquid biopsy that is available.
This test was validated in detail and published for clinical use. Moreover Guardant360® is the only comprehensive test with clinical results. There are numerous publications about Guardant360®.
Guardant Health also regularly takes part in expert conferences and presents latest findings.
Using the following links you can reach the homepage of Guardant Health with the corresponding publications and abstracts of conferences.
Guardant360® - Validation Studies
Selected publications about Guardant360®
- Kim et al. (2017) (http://ascopubs.org/doi/abs/10.1200/PO.16.00059) demonstrated in a prospective stuy the clinical benefit of Guardant360® for advanced solid tumors. Patients treated according to test result had a better outcome.
- Schwaederlé et al. (2017) (http://clincancerres.aacrjournals.org/content/early/2017/05/24/1078-0432.CCR-16-2497) demonstrated that a therapy adjusted to the alterations of the ctDNA leads to therapeutic efficacy.
- Liang et al. (2016) (https://link.springer.com/article/10.1007/s10549-015-3635-5) demonstrated that ctDNA can be used to monitor the response and the disease progress.
- Lanman et al. (2015) (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608804/) describe the analytical and clincial validation of the gene panel which is used for ctDNA evaluation. With digital sequencing that is used for Guardant360® a analytical specificity of 99.9999 % is achieved and almost all false-positive results are eliminated